Recommendations for the medical treatment of rheumatoid artritis;Recommendaciones para el tratamiento médico de la artritis reumatoide

Revista de Investigacion Clinica

Volumn 57, Issue 5, 2005, Pages 735-755

  Diaz Jouanen, Efrain ^a   Abud Mendoza, Carlos ^b   Garza Elizondo, Maria Alberto ^c   Medrano Ramírez, Gabriel ^d   Orozco Alcalá, J Javier ^e   Pacheco Tena, César Francisco ^f   Pineda Villaseñor, Carlos ^g   Pozos Espíndola, Juan Carlos ^h   Ramos Niembro, Francisco ⁱ   Román, Manuel Robles San ^h   Santan Sahagún, Ernesto J ^j,k  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c Medicina UANL   (Mexico)

^d HOSPITAL GENERAL DE MÉXICO   (Mexico)

^e UNIVERSITY OF GUADALAJARA   (Mexico)

^f UNIVERSIDAD AUTÓNOMA DE CHIHUAHUA   (Mexico)

^g INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^h Instituto Nacional de Cardiologia Ignacio Chaávez   (Mexico)

ⁱ UNIVERSIDAD VERACRUZANA   (Mexico)

^j Hospital Regional 20 IMSS   (Mexico)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BCG VACCINE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; GLUCOCORTICOID; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PENICILLIN DERIVATIVE; PLACEBO; PROTEIN ANTIBODY; PROTEIN C; RITUXIMAB; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ANTIRHEUMATIC AGENT;

ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FUNCTIONAL ASSESSMENT; GENETIC ANALYSIS; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; LABORATORY TEST; MONOTHERAPY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROGNOSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT PLANNING; TUBERCULOSIS; DECISION TREE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DECISION TREES; HUMANS; PRACTICE GUIDELINES; PROGNOSIS; RISK FACTORS; TUBERCULOSIS;

EID: 30344467203     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Pincus T. Assessment of long-term outcomes of rheumatoid arthritis. How choices of measures and study designs may lead to apparently different conclusions. Rheum Dis Clin North Am 1995; 2: 1619-54.
2. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000; 39(Suppl 1): 24-9.
3. Brook A, Corbett M. Radiographic changes in early rheumatoid diseases. Ann Rheum Dis. 1977; 36: 71-3.
4. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 585-91.
5. Mottonen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988; 47: 648-53.
6. Van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, Koster AM, van't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 26-34.
7. Erhardt CC, Mumford PA, Venables PJW, Mani RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an 8 year study. Ann Rheum Dis 1989; 48: 7-13.
8. Reilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990; 49: 363-9.
9. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbility. J Rheumatol 1986; 13: 841-5.
10. Mitchell DM, Spitz P, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 20: 706-14.
11. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford). 2001; 40: 1211-20.
12. Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994; 21: 1808-13.
13. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulfasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1: 1036-8.
14. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996; 124: 699-707.
15. Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M'Seffar A, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3-year follow-up on the Hydroxychloroquine in Early Rheumatoid Arthritis (HERA) study. J Rheumatol 2000; 27: 623-9.
16. van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM, et al. On behalf of the Rheumatic Research Foundation, Utrecht, The Netherlands. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 2000; 59: 468-77.
17. Albers JM, Paimela L, Kurki P, Eberhardt KB, Emery P, van't Hof MA, et al. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60: 453-8.
18. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting the response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43: 22-9.
19. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18. Erratum in: Lancet 1998; 351: 220.
20. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
21. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleichsmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving MTX. N Engl J Med 1999; 340: 253-9.
22. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.
23. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully Human anti-tumor necrosis factor monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
24. Smolen JS, Emery P, Bathon J. Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone. Preliminary results of the ASPIRE trial. Ann Rheum Dis 2003; 62(Suppl 1): 64.
25. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24.
26. American College of Rheumatology ad hoc Committee on Clinical Guidelines. Guidelines for Monitoring Drug Therapy in Rheumatoid Arthritis. Arthritis Rheum. 1966; 39: 723-31.
27. Green M, Marzo-Ortega H, McGonagle D, Wakefield R, Proudman S, Conaghan P, et al. Persistence of mild, early inflammatory arthritis. The importance of disease duration, rheumatoid factor and the shared epitope. Arthritis Rheum 1999; 42: 214-8.
28. Tunn EJ, Bacon PA. Differentiating persisting from self limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993; 97-103.
29. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-65.